Galvus launch
July 30, 2010
AUSSIES who have been unable
to reach their target blood glucose
levels on their current type 2
diabetes medication, will soon be
granted access to Galvus via the
PBS from 01 Aug.
When taken in conjunction with
either metformin, a sulfonylurea or
pioglitazone type 2 diabetes
medications Galvus delivers
significant blood glucose reductions.
In addition, in its current tablet
format Galvus has also been
proven to lower blood glucose levels
without affecting body weight or
causing hypoglycaemia.
The announcement of Galvus’
PBS listing coincides with the
release of new research, endorsed
by the Guild, titled Understanding
the challenges patients face in
managing type 2 diabetes.
The study found that only around
17% of participants were able to
correctly identify their blood glucose
target, and one-in-three considered
their diabetes uncontrolled.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 10
